PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND OUTCOMES IN POST-IMMUNE CHECKPOINT INHIBITOR AND POST-PLATINUM-BASED CHEMOTHERAPY AMONG PATIENTS WITH ENDOMETRIAL CANCER IN THE US
Author(s)
Ke Meng, PhD1, Kathleen M. McClain, PhD1, Vimalanand S. Prabhu, PhD1, Srujitha Marupuru, PhD1, Vy Tran, MHS1, Robert Orlowski, MD1, Robin Meng, MD1, Angela K. Green, MD2, Christian Marth, MD3, Vicky Makker, MD2.
1Merck & Co., Inc., Rahway, NJ, USA, 2Memorial Sloan Kettering Cancer Center, New York, NY, USA, 3Medical University Innsbruck, Innsbruck, Austria.
1Merck & Co., Inc., Rahway, NJ, USA, 2Memorial Sloan Kettering Cancer Center, New York, NY, USA, 3Medical University Innsbruck, Innsbruck, Austria.
OBJECTIVES: Endometrial cancer (EC) is the most common gynecological cancer in the US and one of the few cancers with growing incidence. As immune checkpoint inhibitor (ICI) and platinum-based chemotherapy (PBC) usage in EC has increased in earlier (1L) settings, there is a growing unmet medical need for population in post-ICI and post-PBC (Post-ICI-Post-PBC) setting. The study aims to understand patient characteristics, treatment patterns, and outcomes in the Post-ICI-Post-PBC setting.
METHODS: This retrospective study used data from the US-based Flatiron Health Research Database (2013-2025). Adult women treated for EC with prior exposure to ICI and PBC and at least one subsequent treatment were included. Patient demographics, clinical characteristics, and treatment patterns for Post-ICI-Post-PBC setting and prior exposures to ICI/PBC were descriptively summarized. Select outcomes (TOT, TTNT, OS) will be summarized using Kaplan-Meier analysis and presented at the conference.
RESULTS: A total of 251 women were identified as Post-ICI-Post-PBC with 8%, 30%, 30%, and 32% in 1L, 2L, 3L, 4L+, respectively, median age at diagnosis: 69 years. Majority were White (58%), had endometrioid carcinoma (50%) and pMMR/MSS tumors (65%). For dMMR tumors, 13%, 15%, <5%, and <5% were treated with IO monotherapy, doxorubicin monotherapy, PBC, and ICI+PBC+taxane, respectively. For those with pMMR tumors, 17%, <5%, 18%, <5%, and 3%, were treated with doxorubicin, PBC, ICI+TKI, other chemotherapy monotherapy, and ICI monotherapy, respectively. Overall, 93 (38%) patients received some ICI, 83% of which was pembrolizumab, and 24% received chemotherapy monotherapy. Earlier PBC was mostly PBC+taxane (54%). Earlier ICI was monotherapy (70%) for patients with dMMR tumors, and pembrolizumab+lenvatinib (46%) for patients with pMMR tumors.
CONCLUSIONS: Post-ICI-Post-PBC EC patients were generally treated with chemotherapy or an ICI-containing regimen. Overall, there seems to be no consensus on treatment in this setting, highlighting the challenges in treatment sequencing and the need for FDA-approved novel therapies in this setting.
METHODS: This retrospective study used data from the US-based Flatiron Health Research Database (2013-2025). Adult women treated for EC with prior exposure to ICI and PBC and at least one subsequent treatment were included. Patient demographics, clinical characteristics, and treatment patterns for Post-ICI-Post-PBC setting and prior exposures to ICI/PBC were descriptively summarized. Select outcomes (TOT, TTNT, OS) will be summarized using Kaplan-Meier analysis and presented at the conference.
RESULTS: A total of 251 women were identified as Post-ICI-Post-PBC with 8%, 30%, 30%, and 32% in 1L, 2L, 3L, 4L+, respectively, median age at diagnosis: 69 years. Majority were White (58%), had endometrioid carcinoma (50%) and pMMR/MSS tumors (65%). For dMMR tumors, 13%, 15%, <5%, and <5% were treated with IO monotherapy, doxorubicin monotherapy, PBC, and ICI+PBC+taxane, respectively. For those with pMMR tumors, 17%, <5%, 18%, <5%, and 3%, were treated with doxorubicin, PBC, ICI+TKI, other chemotherapy monotherapy, and ICI monotherapy, respectively. Overall, 93 (38%) patients received some ICI, 83% of which was pembrolizumab, and 24% received chemotherapy monotherapy. Earlier PBC was mostly PBC+taxane (54%). Earlier ICI was monotherapy (70%) for patients with dMMR tumors, and pembrolizumab+lenvatinib (46%) for patients with pMMR tumors.
CONCLUSIONS: Post-ICI-Post-PBC EC patients were generally treated with chemotherapy or an ICI-containing regimen. Overall, there seems to be no consensus on treatment in this setting, highlighting the challenges in treatment sequencing and the need for FDA-approved novel therapies in this setting.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
HSD14
Topic
Health Service Delivery & Process of Care
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology